Efficacy of Donepezil in Patients With Chronic Tinnitus
NCT ID: NCT07153991
Last Updated: 2025-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE4
70 participants
INTERVENTIONAL
2021-11-19
2025-12-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multicenter Evaluation of Memory Remediation After TBI With Donepezil
NCT02255799
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
NCT05262023
Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease
NCT01055392
Effects of Donepezil and Memantine on Cognitive Functions After a Sleep Deprivation Challenge in Healthy Volunteers
NCT01461174
Daridorexant for Alzheimer Disease Prevention
NCT07213349
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention Group (donepezil)
35 Participants with tinnitus received donepezil for 3 months, starting with 5 mg daily for the first month and 10 mg daily for the following two months.
Donepezil group
Participants received donepezil for 3 months, starting with 5 mg daily for the first month and 10 mg daily for the following two months
Placebo group
35 Pacients with tinnitus received for 3 months placebo medication
Placebo group
35 Pacients with tinnitus received for 3 months placebo medication
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Donepezil group
Participants received donepezil for 3 months, starting with 5 mg daily for the first month and 10 mg daily for the following two months
Placebo group
35 Pacients with tinnitus received for 3 months placebo medication
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundação de Amparo à Pesquisa do Estado de São Paulo
OTHER_GOV
University of Sao Paulo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elaine Miwa Watanabe
medical doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universidade De São Paulo
São Paulo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1248-6988
Identifier Type: REGISTRY
Identifier Source: secondary_id
CAAE 34251320.5.0000.0068
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.